Medicine – Diabetic Kidney Disease

Diabetic kidney disease, traditionally called diabetic nephropathy, is one of the most important microvascular complications of diabetes mellitus. It is characterised by persistent albuminuria, progressive loss of kidney function, and an increased risk of cardiovascular disease.

Diabetes remains one of the leading causes of end-stage kidney disease (ESKD) in many countries, including the UK.

1. Diabetes as a Cause of End-Stage Kidney Disease

Older teaching commonly states that diabetes is:

The most common cause of ESRF in the UK.

The modern term is:

End-stage kidney disease, or ESKD.

Diabetes remains a major cause of ESKD and renal replacement therapy because chronic hyperglycaemia causes progressive glomerular and vascular injury over many years.

2. Type 1 Diabetes and Nephropathy

The original note states that:

49% of patients with type 1 diabetes develop nephropathy after 20–40 years.

This is an older estimate and is probably too high for many modern cohorts because improved glycaemic control, blood-pressure management, and renoprotective therapy have reduced the incidence.

The key point remains:

The risk of diabetic kidney disease increases with duration of diabetes.

3. Risk Factors for Diabetic Kidney Disease

Important factors that increase the risk of diabetic kidney disease include:

Long duration of diabetes.

Poor glycaemic control.

Hypertension.

Smoking.

Dyslipidaemia.

Obesity.

Family or genetic susceptibility.

4. Pathophysiology

Chronic hyperglycaemia causes structural and functional changes in the glomerulus.

Early changes include:

Glomerular hyperfiltration.

Increased intraglomerular pressure.

Basement membrane thickening.

Mesangial expansion.

Over time, these changes lead to:

Albuminuria.

Glomerulosclerosis.

Progressive decline in GFR.

5. Glomerular Hyperfiltration

In early diabetes, the kidneys may show:

Increased GFR.

This is partly due to changes in afferent and efferent arteriolar tone that increase pressure within the glomerular capillaries.

Persistent:

Intraglomerular hypertension

contributes to progressive glomerular injury.

6. Albuminuria

One of the earliest clinically detectable abnormalities is:

Increased urinary albumin excretion.

Older terminology used:

Microalbuminuria.

Modern terminology generally prefers:

Moderately increased albuminuria.

7. Microalbuminuria – Older Definition

The original note gives:

30–250 mg/day.

Traditional definitions usually use approximately:

30–300 mg of albumin per day.

Therefore, 30–250 mg/day is slightly narrower than the standard older teaching range.

8. Modern Albuminuria Categories

Modern practice commonly uses the:

Urine albumin-to-creatinine ratio, or ACR.

Albuminuria is divided into:

A1 – Normal to mildly increased.

A2 – Moderately increased.

A3 – Severely increased.

This is preferred over the older terms microalbuminuria and macroalbuminuria.

9. Moderately Increased Albuminuria

Moderately increased albuminuria corresponds roughly to:

30–300 mg albumin/day

or an equivalent raised urinary ACR.

This stage may occur before a major fall in GFR.

10. Severely Increased Albuminuria

As disease progresses, albumin excretion may increase substantially.

Older notes may describe:

Proteinuria greater than 0.5 g/day.

However, modern assessment usually focuses on:

Albuminuria categories and urinary ACR

rather than a single total-protein threshold.

11. Persistent Albuminuria

A single abnormal urine test is not enough to diagnose diabetic kidney disease.

Albuminuria should generally be confirmed as:

Persistent

because temporary increases may occur with:

Exercise.

Fever.

UTI.

Marked hyperglycaemia.

Heart failure.

12. Hypertension

Hypertension commonly accompanies diabetic kidney disease.

It can be both:

A cause of faster renal progression

and

A consequence of worsening renal disease.

As nephropathy progresses:

Sodium retention + RAAS activation + vascular disease → worsening hypertension.

13. Nephrotic Syndrome

Advanced diabetic glomerular disease can produce:

Heavy proteinuria.

This may progress to:

Nephrotic syndrome.

Features include:

Marked proteinuria.

Hypoalbuminaemia.

Peripheral oedema.

Hyperlipidaemia.

14. Chronic Kidney Disease

Progressive diabetic kidney disease can cause:

Chronic kidney disease, or CKD.

The older term:

CRF – chronic renal failure

is now generally replaced by:

CKD.

As CKD advances, the patient may develop:

Reduced eGFR.

Anaemia.

Fluid retention.

Electrolyte disturbances.

Uraemic complications.

15. Progression of Diabetic Kidney Disease

A simplified classical sequence is:

Hyperfiltration → moderately increased albuminuria → overt proteinuria → declining GFR → CKD → ESKD.

However, modern understanding recognises that some patients can lose GFR without developing marked albuminuria.

Therefore, diabetic kidney disease is not always perfectly linear.

16. Renal Histology

Diabetic kidney disease causes characteristic structural changes within the glomeruli and renal vasculature.

Important findings include:

Glomerular basement membrane thickening.

Mesangial expansion.

Diffuse glomerulosclerosis.

Nodular glomerulosclerosis.

Arteriolar hyalinosis.

17. Kimmelstiel–Wilson Nodules

The classic biopsy finding is:

Kimmelstiel–Wilson nodules.

These represent:

Nodular mesangial expansion

and are characteristic of advanced diabetic glomerulosclerosis.

18. Nodular Glomerulosclerosis

Kimmelstiel–Wilson lesions are rounded areas of:

Mesangial matrix accumulation

within the glomerulus.

This pattern is also called:

Nodular diabetic glomerulosclerosis.

It is highly characteristic in the appropriate clinical setting, although nodular sclerosis is not absolutely unique to diabetes.

19. Diffuse Glomerulosclerosis

Before or alongside nodular lesions, diabetes may cause:

Diffuse mesangial expansion.

This produces progressive reduction in available glomerular capillary surface area.

Over time:

Glomerular filtration declines.

20. Arteriolar Hyalinosis

Diabetes commonly causes:

Hyaline arteriolosclerosis.

An important distinction from uncomplicated hypertension is that diabetes may affect both:

Afferent arterioles

and

Efferent arterioles.

This is a classic pathological clue.

21. When Kidney Biopsy Is Needed

Diabetic kidney disease is often diagnosed clinically rather than by biopsy.

Biopsy may be considered when features suggest another renal disease, for example:

Rapidly declining kidney function.

Active urinary sediment.

Marked haematuria.

Abrupt onset of heavy proteinuria.

Absence of other diabetic microvascular disease in a suspicious context.

22. Diabetic Retinopathy and Nephropathy

In type 1 diabetes, diabetic nephropathy often occurs alongside:

Diabetic retinopathy.

The absence of retinopathy in a patient with major proteinuria may increase suspicion of another renal diagnosis, particularly in type 1 diabetes.

In type 2 diabetes, the association is less consistent.

23. Treatment Principles

Management aims to slow loss of kidney function and reduce cardiovascular risk.

Important components include:

Good glycaemic control.

Blood-pressure control.

Reduction of albuminuria.

RAAS blockade where indicated.

SGLT2 inhibitor therapy in suitable patients.

Cardiovascular risk reduction.

24. ACE Inhibitors

ACE inhibitors are important in diabetic kidney disease, especially when there is:

Hypertension and albuminuria.

They reduce:

Systemic blood pressure

and

Intraglomerular pressure.

This decreases albuminuria and can slow renal progression.

25. Angiotensin II Receptor Blockers

Angiotensin II receptor blockers, or ARBs, provide similar renoprotective effects.

They are often used when:

ACE inhibitors are not tolerated.

26. Do Not Routinely Combine ACE Inhibitors and ARBs

An important modern correction is:

ACE inhibitors and ARBs should not routinely be used together.

Dual blockade increases the risk of:

Hyperkalaemia.

Acute kidney injury.

Hypotension.

without sufficient additional renal benefit.

Therefore:

ACE inhibitor OR ARB, not routinely both.

27. SGLT2 Inhibitors

A major modern addition is the use of:

SGLT2 inhibitors.

Examples include:

Empagliflozin.

Dapagliflozin.

Canagliflozin.

In appropriate patients, these drugs reduce:

Progression of CKD.

Albuminuria.

Heart-failure events.

They are now central renoprotective therapy in many patients with diabetic CKD.

28. How SGLT2 Inhibitors Protect the Kidney

SGLT2 inhibitors increase sodium delivery to the macula densa.

This helps restore:

Tubuloglomerular feedback

and reduces:

Intraglomerular pressure.

Therefore:

SGLT2 inhibition → reduced hyperfiltration → renal protection.

29. Glycaemic Control

Good glycaemic control reduces the development and progression of diabetic microvascular complications.

Therefore:

Tight or individualised glycaemic control

is an important part of preventing diabetic kidney disease.

However, targets should be individualised according to:

Age.

Comorbidity.

Hypoglycaemia risk.

Duration of diabetes.

Kidney function.

30. Blood-Pressure Control

Good blood-pressure control is essential because hypertension markedly accelerates progression of diabetic kidney disease.

The original target:

<130/75 mmHg

reflects older teaching.

Modern guidelines generally individualise targets rather than using 130/75 mmHg for every patient.

31. Modern Blood-Pressure Targets

In many patients with diabetic CKD and albuminuria, a target around:

<130/80 mmHg

may be considered if tolerated, though exact targets vary between guidelines and individual clinical circumstances.

The key principle is:

Avoid uncontrolled hypertension while preventing symptomatic hypotension or renal hypoperfusion.

32. Finerenone

Another modern therapy in selected patients with:

Type 2 diabetes + CKD + persistent albuminuria

despite appropriate ACE inhibitor or ARB therapy is:

Finerenone.

This is a:

Non-steroidal mineralocorticoid receptor antagonist.

It can reduce renal and cardiovascular events in suitable patients.

33. Lipid and Cardiovascular Risk Management

Patients with diabetic kidney disease have a high cardiovascular risk.

Management therefore also includes:

Statin therapy where indicated.

Smoking cessation.

Weight management.

Exercise as appropriate.

Management of other cardiovascular risk factors.

34. Monitoring

Patients should be monitored with:

Serum creatinine and eGFR.

Urinary ACR.

Serum potassium.

Blood pressure.

HbA1c.

Monitoring is especially important after starting or increasing:

ACE inhibitors.

ARBs.

SGLT2 inhibitors.

Mineralocorticoid receptor antagonists.

35. Diabetic Kidney Disease – Note Form

Importance:

Diabetes is one of the leading causes of ESKD.

Type 1 diabetes:

Risk increases with duration.

Older estimates of almost 50% developing nephropathy are higher than many modern cohorts.

Early renal change:

Glomerular hyperfiltration.

Early clinical marker:

Moderately increased albuminuria.

Older term:

Microalbuminuria.

Approximately 30–300 mg/day.

Progression:

Increasing albuminuria.

Hypertension.

Heavy proteinuria.

Nephrotic syndrome.

Declining GFR.

CKD.

ESKD.

Histology:

GBM thickening.

Mesangial expansion.

Diffuse glomerulosclerosis.

Kimmelstiel–Wilson nodules.

Afferent and efferent arteriolar hyalinosis.

Treatment:

Good glycaemic control.

Good blood-pressure control.

ACE inhibitor OR ARB where indicated.

SGLT2 inhibitor in appropriate patients.

Finerenone in selected type 2 diabetic CKD with persistent albuminuria.

Cardiovascular risk reduction.

36. Important Corrections to the Original Notes

The older term:

ESRF

is better replaced by:

ESKD – end-stage kidney disease.

The statement:

“49% of type 1 diabetics develop nephropathy after 20–40 years”

should not be treated as a fixed modern figure.

Risk varies greatly and has fallen with improved diabetes and blood-pressure management.

The older definition:

Microalbuminuria 30–250 mg/day

is better written as approximately:

30–300 mg albumin/day

or, preferably, assessed using:

Urinary albumin-to-creatinine ratio.

The treatment statement:

“ACE inhibitors and angiotensin II blockers”

should not imply combining them.

Remember:

ACE INHIBITOR OR ARB – NOT ROUTINE DUAL THERAPY.

The blood-pressure target:

<130/75 mmHg

is an older fixed target.

Modern care generally uses:

Individualised targets, often around <130/80 mmHg when appropriate and tolerated.

Key Clinical Pattern

Think:

DIABETES → GLOMERULAR HYPERFILTRATION → ALBUMINURIA → GLOMERULOSCLEROSIS → FALLING GFR → CKD / ESKD.

The classic pathology is:

KIMMELSTIEL–WILSON NODULES = NODULAR DIABETIC GLOMERULOSCLEROSIS.

Another high-yield pathology clue is:

DIABETES → HYALINOSIS OF BOTH AFFERENT AND EFFERENT ARTERIOLES.

For treatment remember:

GLYCAEMIC CONTROL + BLOOD-PRESSURE CONTROL + ACEi/ARB + SGLT2 INHIBITOR WHEN APPROPRIATE.

And:

DO NOT ROUTINELY COMBINE ACE INHIBITORS WITH ARBs.